

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandra, Virguna 22313-1450 www.usplo.gov

CONFIRMATION NO. ATTORNEY DOCKET NO. FIRST NAMED INVENTOR FILING DATE APPLICATION NO. 6685 032796-014 John P. Carulli 04/05/2000 09/543,771 08/27/2003 21839 EXAMINER BURNS DOANE SWECKER & MATHIS L L P KAUSHAL, SUMESH POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404 PAPER NUMBER ART UNIT 1636 DATE MAILED: 08/27/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	
		09/543,771	CARULLI ET AL.	
	Office Action Summary	Examiner	Art Unit	
		Sumesh Kaushal P	h.D. 1636	
	The MAILING DATE of this communication app	pears on the cover sl	neet with the correspondence address	
Period	I for Ponly			
TH - E - 1 - 1 - 1 - 1 - 4	SHORTENED STATUTORY PERIOD FOR REPL'S IEMAILING DATE OF THIS COMMUNICATION.  Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply in NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute any reply received by the Office later than three months after the mailing parned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however y within the statutory minimum will apply and will expire SIX	may a reply be timely filed  im of thirty (30) days will be considered timely.  (6) MONTHS from the mailing date of this communication.	
Status	- filed on 12	June 2 <u>003</u> .		
		his action is non-fina	al.	
2a)	This action to the second seco	once except for for	nal matters, prosecution as to the merits is	
	Since this application is in condition for allow closed in accordance with the practice under sition of Claims	Ex parte Quayle, 1	935 C.D. 11, 453 O.G. 213.	
4	√ Claim(s) <u>1 and 31-36</u> is/are pending in the ap	oplication.		
- /	4a) Of the above claim(s) is/are withdra	awn from considera	ion.	
5	Claim(s) 1 and 31-36 is/are allowed.			
	Claim(s) is/are rejected.			
	7) Claim(s) is/are objected to.			
,   8	) Claim(s) are subject to restriction and/	or election requiren	nent.	
	ication Papers			
	ાડી The specification is objected to by the Examir	ner.		
10	The drawing(s) filed on is/are: a) acc	cepted or b) 🔲 objecte	ed to by the Examiner.	
	Applicant may not request that any objection to	the drawing(s) be held	in abeyance. See 37 CFR 1.03(a).	
11	) The proposed drawing correction filed on	is: a)∐ approve	d b)[_] disapproved by the Examiner.	
	If approved, corrected drawings are required in	reply to this Office act	ion.	
12	2) The oath or declaration is objected to by the I	Examiner.		
Drio	rity under 35 U.S.C. §§ 119 and 120			
1:	3) Acknowledgment is made of a claim for fore	ign priority under 35	5 U.S.C. § 119(a)-(d) or (f).	
	a) ☐ All b) ☐ Some * c) ☐ None of:			
	1 Certified copies of the priority docume	ents have been rece	ived.	
	2 Certified copies of the priority docume	ents have been rece	eived in Application No	
	Copies of the certified copies of the p     application from the International     See the attached detailed Office action for a	riority documents h	ave been received in this National Stage 17.2(a)).	
	* See the attached detailed Office action for a tag.  4) Acknowledgment is made of a claim for dome	estic priority under 3	5 U.S.C. § 119(e) (to a provisional application	
	The Association of the foreign language	provisional applicat	ion has been received.	
	a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.			
	chment(s)	47.	Interview Summary (PTO-413) Paper No(s)	
1) [ 2) [ 3) [	Notice of References Cited (PTO-892)  Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No	(s) 6) \( \bigsiz \)		

Application/Control Number: 09/543,771

Art Unit: 1636

## Notice To Comply

With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Specifically the application fails to comply with CFR 1.821(d), which states:

(d) Where the description or claims of a patent application discuss a sequence that is set forth in the "Sequence Listing" in accordance with paragraph (c) of this section, reference must be made to the sequence by use of the sequence identifier, preceded by "SEQ ID NO: " in the text of the description or claims, even if the sequence is also embedded in the text of the description or claims of the patent application (see MPEP 2422.03).

For compliance with sequence rules, it is necessary to include the sequence in the "Sequence Listing" and identify them with SEQ ID NO. In general, any sequence that is disclosed and/or claimed as a sequence, i.e., as a string of particular bases or amino acids, and that otherwise meets the criteria of 37 CFR 1.821(a), must be set forth in the "Sequence Listing." (see MPEP 2422.03).

The instant specification fails to comply with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures because: The specification fail to provide SEQ ID NO(s) for the nucleotide sequences disclosed on pages 31, 33-3746, 67, 69-70, 75 and for Fig-6A-J.

The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification

For the response to this office action to be complete, Applicants are required to comply with the Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the SIX MONTHS statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Application/Control Number: 09/543,771

Art Unit: 1636

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office. Please direct all replies to the United States Patent and Trademark Office via one of the following:

### Electronically submitted through EFS-Bio

(http://www.uspto.gov/ebc/efs/downloads/documents.htm),

EFS Submission User Manual - ePAVE)

#### Mailed to:

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

# Mailed by Federal Express, United Parcel Service or other delivery service to:

U. S. Patent and Trademark Office 2011 South Clark Place Customer Window, Box Sequence Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

## Hand Carried directly to the Customer Window at:

2011 South Clark Place Crystal Plaza Two, Lobby, Room 1B03, Box Sequence, Arlington, Virginia 22202

Any inquiry concerning this communication or earlier communications from the examiner should be directed Sumesh Kaushal whose telephone number is 703-305-6838.

S. Kaushal

PATENT EXAMINER

REMY YUCEL, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600